Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT
In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings.
This activity can be accessed using the following URL: www.peerview.com/UPA
- Medical Oncologists
- BMT Specialists
- BMT Nurse Specialists
- Other Clinicians Involved in the Management of AML
Upon completion of this activity, participants should be better able to:
|•||Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML|
|•||Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies|
|•||Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting|
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas Pharma Global Development, Inc., Bristol Myers Squibb, and Gilead Sciences, Inc.
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Actinium Pharmaceuticals, Inc.; Agios Pharmaceuticals Inc.; Amgen; Amphivena Therapeutics; Argenx; Array BioPharma; Astellas Pharma US, Inc.; AstraZeneca; Astex Therapeutics; Bayer; Bristol Myers Squibb; Celgene Corporation; Celltrion; Daiichi Sankyo, Inc.; Eisai Inc.; Epizyme; F. Hoffmann-La Roche/Genentech, Inc.; GlaxoSmithKline; Helsinn; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; MEI Pharma-IDMC Chair; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Orsenix; Otsuka America Pharmaceutical, Inc.; Pfizer; Sandoz; Takeda Pharmaceutical Company Limited; and Trovagene.
Grant/Research Support from Cellectis.
James M. Foran, MD, FRCPC
Associate Professor of Oncology
Chair, Acute Leukemia & Myeloid Neoplasm Disease Group
Mayo Clinic Cancer Center
James M. Foran, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cetara; Novartis Pharmaceuticals Corporation; Pfizer; Revolution Medicines; Sanofi; Servier Laboratories; Stemline Therapeutics, Inc.; Syros Pharmaceuticals, Inc.; and TAIHO ONCOLOGY, INC.
Grant/Research Support from AbbVie Inc.; Actinium Pharmaceuticals, Inc.; Aprea Therapeutics; Aptose Biosciences Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; H3 Biomedicine Inc.; Kura Oncology, Inc.; Sellas; Takeda Pharmaceutical Company Limited; Trillium Therapeutics Inc.; and Xencor, Inc. Research Support goes to Institution.
Anita D’Souza, MD
Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.